Detection of ERBB2 (HER2) Gene Amplification Events in Cell-Free DNA and Response to Anti-HER2 Agents in a Large Asian Cancer Patient Cohort
Background: HER2 antagonists have marked activity and are approved for the treatment of HER2 overexpressing breast and gastric cancers. Recent studies have shown that ERBB2 (HER2) gene amplification and overexpression may also be actionable in other tumor types. Inter- and intratumoral heterogeneity...
Main Authors: | Jeeyun Lee, Aleksandra Franovic, Yukimasa Shiotsu, Seung Tae Kim, Kyoung-Mee Kim, Kimberly C. Banks, Victoria M. Raymond, Richard B. Lanman |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-04-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2019.00212/full |
Similar Items
-
ERBB2 (HER2) amplifications and co-occurring KRAS alterations in the circulating cell-free DNA of pancreatic ductal adenocarcinoma patients and response to HER2 inhibition
by: Afsaneh Barzi, et al.
Published: (2024-02-01) -
BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings
by: Pancrazzi Pancrazzi, et al.
Published: (2023-09-01) -
Clinical application of targeted tumour sequencing tests for detecting ERBB2 amplification and optimizing anti-HER2 therapy in gastric cancer
by: Hiroshi Ichikawa, et al.
Published: (2024-06-01) -
Expression of HER2/c-erbB-2, EGFR protein in gastric carcinoma and its clinical significance
by: Cheng Guoxiong, et al.
Published: (2019-05-01) -
Molecular characteristics of gastric cancer with ERBB2 amplification
by: Dongyan Cao, et al.
Published: (2023-08-01)